An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
The objective of this study is to if MK-6482 works better or worse than everiolimus in previously treated subjects with advanced or metastatic RCC.
Previously Treated Advanced Renal Cell Carcinoma
Age eighteen years or older on the day of consent with unresectable, locally advanced or metastatic clear cell RCC and has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology. Has received previous treatment for locally advanced or metastatic RCC with a PD-1/L1 checkpoint inhibitor.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until progression. Option to continue to receive study drug after progression as long as you are seeing clinical benefit.
Knight Cancer Institute Clinical Trials